相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1908
进行中（未招募）
1
100.0%
暂无批准数据
- Yanagisawa Masashi of the University of Tsukuba shared the Lasker Basic Medical Research Award with Stanford's Emmanuel Mignot for identifying orexin and its role in narcolepsy. - Three Chugai Pharmaceutical researchers received the Clinical Medical Research Award for developing Hemlibra, an antibody treatment for hemophilia A. - The four are the first Japanese scientists in 12 years to win the awards, which the Lasker Foundation will present in New York on September 17. - Lasker Awards are widely viewed as predictors of Nobel Prizes, with past winner Shinya Yamanaka later receiving the 2012 Nobel Prize in Physiology or Medicine.
- A new analysis of the DIETFITS trial suggests genetic predisposition interacts with saturated fat intake to drive LDL cholesterol increases on low-carb diets. - Researchers combined thousands of genetic variants into a polygenic score to estimate each participant's overall tendency toward higher or lower LDL cholesterol. - Among low-carb dieters, those with the highest genetic risk showed the largest LDL increases when consuming more saturated fat, a pattern not seen on low-fat diets. - The findings underscore that dietary responses are highly individualized, making cholesterol monitoring important rather than assuming one rule applies to everyone.
- A Stanford-led study published in Science identifies tissue-resident macrophages as central coordinators of age-related decline across multiple organs, rather than passive bystanders. - Researchers found that EP2 receptor signaling increases in aged macrophages, suppressing their metabolism and ability to clear senescent neutrophils from tissues. - Blocking EP2 in aged mice restored macrophage cleanup function, leading to healthier heart function, reduced frailty, less muscle loss, and improved cognitive performance. - Human liver and heart tissue analyses confirmed the same EP2-driven patterns, suggesting the underlying biology is shared across species.
- Nearly 30% of patients with cancer-related germline mutations reported that none of their relatives underwent genetic testing, despite almost 90% viewing it as their responsibility to inform family members. - Medical oncologists and cancer surgeons lag significantly behind genetic counselors in encouraging patients to discuss germline testing results with relatives, with only about one-third of oncologists providing such encouragement. - An Estonian study found 19.7% of healthy family members of breast and ovarian cancer patients carried pathogenic variants, including 34% of men tested, underscoring the value of early genetic risk assessment. - Researchers are developing interventions like the GIFT online platform, which demonstrated that 91.3% of enrolled relatives completed genetic testing, aiming to close the persistent cascade testing gap.
- Bio Usawa has appointed Dr. Aida Habtezion, former Chief Medical Officer and Head of Worldwide Medical & Safety at Pfizer, to its Board of Directors. - Dr. Habtezion brings extensive experience in global biopharmaceutical leadership, translational research, and academic medicine, including a tenured professorship at Stanford University School of Medicine. - The appointment comes as Bio Usawa accelerates efforts to build sustainable biomanufacturing capacity in Africa and expand access to biologic medicines across the continent. - The company aims to strengthen regional health security and contribute to greater global health equity through local manufacturing and strategic partnerships.
- BioMendics is developing TolaSure, a topical therapy designed to strengthen keratinocyte integrity and reduce blister formation at the molecular level for Epidermolysis Bullosa Simplex patients. - The company's TAMES-02 trial, launched in August 2025, is a multicenter, randomized, double-blind, placebo-controlled study evaluating TolaSure in patients aged four years and older with moderate to severe EB Simplex. - TolaSure has received FDA Orphan Drug Designation and Rare Pediatric Disease Voucher status, positioning it as a potential first disease-modifying therapy for a condition affecting an estimated 35,000 patients in the U.S. - Early studies showed meaningful reduction in blistering, with the current trial focusing on blister surface area changes and plantar blistering assessment over a 6-month treatment period.
- Quadriga BioSciences announced positive Phase IIa interim results for QBS72S, showing 90%, 60%, and 40% survival rates at 1, 3, and 12 months respectively in breast cancer patients with leptomeningeal disease. - The LAT1-targeted chemotherapeutic demonstrated both radiographic stability and improvements in neurologic symptoms, with 4 out of 10 patients surviving beyond 12 months. - QBS72S was well tolerated in heavily pre-treated patients and addresses a critical unmet need, as leptomeningeal disease currently has no approved treatments and typically carries a 2-4 month survival expectation.
- Hermes Biosciences raised seed funding led by Genoa Ventures to commercialize its automated extracellular vesicle isolation platform by 2026. - The company's nanofiltration technology delivers up to 10 times more vesicles than ultracentrifugation while preserving vesicle integrity and molecular content. - Extracellular vesicles carry disease-specific molecular cargo that could transform early disease detection and therapeutic development across cancer and degenerative diseases. - Current EV isolation methods face significant bottlenecks including slow processing, inconsistency, and poor scalability for clinical workflows.
- Kernal Bio received up to $48 million from ARPA-H to advance its in vivo CAR-T cell therapy program KR-402, targeting multiple sclerosis and B-cell malignancies including acute lymphoblastic leukemia and large B-cell lymphoma. - The company's mRNA 2.0 platform uses selective mRNA and targeted lipid nanoparticles to reprogram T cells directly inside the body, potentially reducing manufacturing costs by 100-fold compared to traditional ex vivo CAR-T therapies. - The in vivo approach eliminates the need for toxic lymphodepletion procedures and reduces the three-week vein-to-vein turnaround time associated with current CAR-T treatments. - Kernal Bio will collaborate with Stanford University School of Medicine, Dana-Farber Cancer Institute, and The Jackson Laboratory to develop this next-generation cell therapy technology.
- Idorsia has partnered with Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a three-phase program aimed at standardizing treatment and generating real-world evidence for difficult-to-control hypertension patients. - The initiative will develop AI-powered digital tools including a care algorithm, personalized risk scoring system, and patient-facing platforms to improve identification and management of hypertension patients requiring multiple medications. - IMPACT-HTN represents the first program of its kind to systematically address care coordination challenges for patients with difficult-to-control hypertension, potentially transforming treatment protocols for the estimated 50% of U.S. adults affected by hypertension. - The collaboration will explore how newer treatments like Idorsia's TRYVIO (aprocitentan), the first systemic hypertension treatment targeting a new pathway in over 30 years, can be integrated into modernized care pathways.
